351 related articles for article (PubMed ID: 17908053)
1. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and therapeutic prospects in dementia.
Cacabelos R
Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
Cacabelos R
Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
5. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
Cacabelos R
Neuropsychiatr Dis Treat; 2007 Jun; 3(3):303-33. PubMed ID: 19300564
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
7. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
8. Genomics and pharmacogenomics of dementia.
Cacabelos R; Martínez-Bouza R
CNS Neurosci Ther; 2011 Oct; 17(5):566-76. PubMed ID: 20718828
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Ma SL; Tang NLS; Wat KHY; Tang JHY; Lau KH; Law CB; Chiu J; Tam CCW; Poon TK; Lin KL; Kng CPL; Kong HL; Chan TY; Chan WC; Lam LCW
Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):302-307. PubMed ID: 31064198
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic protocols in CNS disorders and dementia.
Cacabelos R
Neurodegener Dis; 2010; 7(1-3):167-9. PubMed ID: 20197699
[TBL] [Abstract][Full Text] [Related]
13. Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics.
Cacabelos R; Carril JC; Cacabelos N; Kazantsev AG; Vostrov AV; Corzo L; Cacabelos P; Goldgaber D
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871086
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
Cacabelos R; Naidoo V; Martínez-Iglesias O; Corzo L; Cacabelos N; Pego R; Carril JC
Methods Mol Biol; 2022; 2547():275-387. PubMed ID: 36068470
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
[TBL] [Abstract][Full Text] [Related]
16. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
Varsaldi F; Miglio G; Scordo MG; Dahl ML; Villa LM; Biolcati A; Lombardi G
Eur J Clin Pharmacol; 2006 Sep; 62(9):721-6. PubMed ID: 16845507
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and therapeutic strategies for dementia.
Cacabelos R
Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
Cacabelos R
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):673-701. PubMed ID: 32520597
[TBL] [Abstract][Full Text] [Related]
19. Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Xiao T; Jiao B; Zhang W; Tang B; Shen L
CNS Drugs; 2016 Oct; 30(10):899-907. PubMed ID: 27282366
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
Cacabelos R
Expert Opin Pharmacother; 2005 Oct; 6(12):1967-87. PubMed ID: 16197352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
